CureVac N.V. Reports Annual Meeting Voting Results
| Field | Detail |
|---|---|
| Company | Curevac N.V. |
| Form Type | 6-K |
| Filed Date | Jun 24, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, voting-results, financials
TL;DR
CureVac shareholders approved 2024 financials & profit use at the June 24th meeting.
AI Summary
On June 24, 2025, CureVac N.V. announced the voting results from its Annual General Meeting of Shareholders. Key resolutions included the approval of the annual financial statements for 2024 and the appropriation of net profits. The company also disclosed details regarding the composition of its Supervisory Board.
Why It Matters
Shareholder approval of financial statements and profit appropriation is crucial for corporate governance and financial transparency. The composition of the Supervisory Board impacts the company's strategic oversight.
Risk Assessment
Risk Level: low — This filing is a routine announcement of voting results from an annual shareholder meeting and does not introduce new material risks.
Key Players & Entities
- CureVac N.V. (company) — Registrant
- June 24, 2025 (date) — Date of press release
- 2024 (date) — Fiscal year for financial statements
FAQ
What was the primary purpose of the June 24, 2025 press release?
The press release announced the voting results of CureVac N.V.'s Annual General Meeting of Shareholders.
Which financial statements were approved by shareholders?
The annual financial statements for the year 2024 were approved.
What other key resolutions were passed at the meeting?
Shareholders also approved the appropriation of net profits and resolutions concerning the Supervisory Board.
What is CureVac N.V.'s principal executive office address?
The principal executive office is located at Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany.
Under which SEC Act is this Form 6-K filed?
This Form 6-K is filed pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 24, 2025 regarding CureVac N.V..